The Hematologic Malignancies Disease Management Group of the Perlmutter Cancer Center is investigating the etiology and treatment of lymphomas, leukemia, multiple myeloma, and other malignancies of the blood and bone marrow. The group brings together not only clinical and basic science investigators who focus on these diseases, but also chemists, molecular biologists, and specialists in bioinformatics and computational biology. The Hematologic Malignancies Group is working on clinical trials that are evaluating emerging agents for the care and treatment of patients with malignancies of the blood and bone marrow.
The research group is working to:
- Discover new research areas that could benefit patient care, including efforts to bring research findings from the lab to the patient and information from patients back to the lab.
- Study the molecular underpinnings and genetic roots of lymphoma development (lymphomagenesis) to help identify novel targets for innovative drug development.
- Investigate the fundamental biology of multiple myeloma and develop and assess targeted therapies that could have greater effectiveness and fewer side effects than conventional approaches.
- Continue to expand its state-of-the-art bone marrow transplant program, which uses both autologous and donor bone marrow and novel methods to minimize toxicities.
- Investigate nonmalignant hematologic conditions, such as coagulation problems, myeloproliferative disorders, and paroxysmal nocturnal hemoglobinuria (PNH).